ATE265430T1 - Neuartige vitamin-d analoge - Google Patents

Neuartige vitamin-d analoge

Info

Publication number
ATE265430T1
ATE265430T1 AT00943703T AT00943703T ATE265430T1 AT E265430 T1 ATE265430 T1 AT E265430T1 AT 00943703 T AT00943703 T AT 00943703T AT 00943703 T AT00943703 T AT 00943703T AT E265430 T1 ATE265430 T1 AT E265430T1
Authority
AT
Austria
Prior art keywords
analogue
new vitamin
vitamin
phenyl
alkyl
Prior art date
Application number
AT00943703T
Other languages
English (en)
Inventor
Claus Aage Bretting
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Application granted granted Critical
Publication of ATE265430T1 publication Critical patent/ATE265430T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5085Supracellular entities, e.g. tissue, organisms of invertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
AT00943703T 1999-08-04 2000-07-11 Neuartige vitamin-d analoge ATE265430T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14720099P 1999-08-04 1999-08-04
PCT/DK2000/000389 WO2001010829A1 (en) 1999-08-04 2000-07-11 Novel vitamin d analogues

Publications (1)

Publication Number Publication Date
ATE265430T1 true ATE265430T1 (de) 2004-05-15

Family

ID=22520639

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00943703T ATE265430T1 (de) 1999-08-04 2000-07-11 Neuartige vitamin-d analoge

Country Status (19)

Country Link
US (1) US6573255B1 (de)
EP (1) EP1206448B1 (de)
JP (2) JP2003506435A (de)
KR (1) KR20020022792A (de)
CN (1) CN1167678C (de)
AT (1) ATE265430T1 (de)
AU (1) AU770771B2 (de)
CA (1) CA2381910A1 (de)
CZ (1) CZ2002392A3 (de)
DE (1) DE60010276T2 (de)
DK (1) DK1206448T3 (de)
ES (1) ES2216908T3 (de)
HK (1) HK1049148B (de)
HU (1) HUP0202305A3 (de)
NZ (1) NZ516913A (de)
PL (1) PL364698A1 (de)
PT (1) PT1206448E (de)
RU (1) RU2228928C2 (de)
WO (1) WO2001010829A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
WO2005027930A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylene-19-nor-vitamin d derivatives for the treatment of osteosarcoma
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
KR20100082840A (ko) 2007-09-27 2010-07-20 에스체아 히기에너 프로덕츠 악티에볼라그 클레이결합된 폴리머 겔
CN103922984B (zh) * 2014-04-24 2016-08-24 湖南华腾制药有限公司 西奥骨化醇的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254799A (en) * 1985-01-18 1993-10-19 Plant Genetic Systems N.V. Transformation vectors allowing expression of Bacillus thuringiensis endotoxins in plants
DE3715114A1 (de) * 1987-05-06 1988-11-17 Krause Hans Verfahren und einrichtung zum toxizitaetsnachweis in oberflaechengewaessern sowie in trink- und brauchwasser
GB9206648D0 (en) 1992-03-26 1992-05-06 Leo Pharm Prod Ltd Chemical compounds
CA2111521A1 (en) * 1993-12-15 1995-06-16 Stroud Water Research Center, Inc. Mayfly centroptilum triangulifer as a bioassay organism
KR20010012770A (ko) * 1997-05-22 2001-02-26 세파론, 인코포레이티드 비타민 d 유사체 및 그 뉴런 효과

Also Published As

Publication number Publication date
AU770771B2 (en) 2004-03-04
US6573255B1 (en) 2003-06-03
ES2216908T3 (es) 2004-11-01
JP4971571B2 (ja) 2012-07-11
EP1206448B1 (de) 2004-04-28
CN1167678C (zh) 2004-09-22
RU2228928C2 (ru) 2004-05-20
HUP0202305A3 (en) 2003-10-28
PL364698A1 (en) 2004-12-13
NZ516913A (en) 2003-11-28
PT1206448E (pt) 2004-08-31
HK1049148A1 (en) 2003-05-02
HK1049148B (zh) 2005-03-11
CZ2002392A3 (cs) 2002-11-13
DE60010276D1 (de) 2004-06-03
CA2381910A1 (en) 2001-02-15
DE60010276T2 (de) 2005-04-21
DK1206448T3 (da) 2004-08-09
JP2003506435A (ja) 2003-02-18
AU5807200A (en) 2001-03-05
JP2003506067A (ja) 2003-02-18
HUP0202305A2 (en) 2002-10-28
CN1372544A (zh) 2002-10-02
KR20020022792A (ko) 2002-03-27
EP1206448A1 (de) 2002-05-22
WO2001010829A1 (en) 2001-02-15

Similar Documents

Publication Publication Date Title
RU2008132204A (ru) Соединения для лечения метаболических заболеваний
CO4700576A1 (es) Nuevos taxoides, su preparacion y las composiciones farmaceuticas que los contienen
DE69325454T2 (de) Taxol-derivate
DK0984778T3 (da) Neuropeptid-Y-ligander
DE60235900D1 (de) Osuppressivum
AU1497997A (en) Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
ES2177058T3 (es) Compuestos eter piperidinilaminometil trifluorometil ciclicos como antagonistas de la sustancia p.
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
AR004965A1 (es) Procedimiento de preparacion de derivados de fenilimidazolidina
ATE265430T1 (de) Neuartige vitamin-d analoge
DK0766699T3 (da) Esterificerede polyanioniske cyclodextriner som inhibitorer af proliferation af glatte muskelceller
DE69724646D1 (de) 16-ene-vitamin d derivate
TR200100740T2 (tr) Tiyazolilsinnamonitriller ve haşere kontrol edici ajanlar
RS20060206A (en) Aminopyridine-derivatives as inducible no-synthase inhibitors
DE60126864D1 (de) Verfahren zur Herstellung von (E,Z) 3-(2-aminoethoxyimino)-androstane-6,17-dione und Analoge
CO5011097A1 (es) Derivados de 8-azabiciclo [3.2.1]octan-3-metanamina .
ES2190781T3 (es) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano.
NZ334367A (en) Compositions comprising a carbanate and a valine amide for controlling harmful fungi
ES8507525A1 (es) Procedimiento para preparar 3-acil-2-nitrometilentetrahidro-2h-1, 3-tiazinas
TR199901284A2 (xx) Ester bile�imleri.
ECSP961890A (es) Benzotiofenos lipofilos (caso x- 10395)
ATE238781T1 (de) Verwendung von katecholderivaten als proteinaseinhibitoren
ES2145899T3 (es) Derivados de feniltio-oxazolina.
DK1140932T3 (da) Derivater af benzo-1,8-naphtyridin
ES2184311T3 (es) Polioxaalcanocarboxilatos de estaño y composiciones que los contienen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1206448

Country of ref document: EP

REN Ceased due to non-payment of the annual fee